463 related articles for article (PubMed ID: 28984291)
1. New perspectives for targeting RAF kinase in human cancer.
Karoulia Z; Gavathiotis E; Poulikakos PI
Nat Rev Cancer; 2017 Nov; 17(11):676-691. PubMed ID: 28984291
[TBL] [Abstract][Full Text] [Related]
2. Current Insights of BRAF Inhibitors in Cancer.
Agianian B; Gavathiotis E
J Med Chem; 2018 Jul; 61(14):5775-5793. PubMed ID: 29461827
[TBL] [Abstract][Full Text] [Related]
3. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II RAF kinase inhibitors in cancer therapy.
Turajlic S; Ali Z; Yousaf N; Larkin J
Expert Opin Investig Drugs; 2013 Jun; 22(6):739-49. PubMed ID: 23642225
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Raf kinases in human cancer: the Raf dimer dilemma.
Durrant DE; Morrison DK
Br J Cancer; 2018 Jan; 118(1):3-8. PubMed ID: 29235562
[TBL] [Abstract][Full Text] [Related]
7. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
Wada M; Horinaka M; Yamazaki T; Katoh N; Sakai T
PLoS One; 2014; 9(11):e113217. PubMed ID: 25422890
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
[TBL] [Abstract][Full Text] [Related]
9. Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer.
Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Pan YL
Cancer Manag Res; 2018; 10():2289-2301. PubMed ID: 30122982
[TBL] [Abstract][Full Text] [Related]
10. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
12. Raf kinase inhibitors in oncology.
Strumberg D; Seeber S
Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
[TBL] [Abstract][Full Text] [Related]
13. Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma.
Rajakulendran T; Adam DN
Int J Dermatol; 2014 Dec; 53(12):1428-33. PubMed ID: 25311997
[TBL] [Abstract][Full Text] [Related]
14. Tumor adaptation and resistance to RAF inhibitors.
Lito P; Rosen N; Solit DB
Nat Med; 2013 Nov; 19(11):1401-9. PubMed ID: 24202393
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
17. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
18. BRAF inhibitors in cancer therapy.
Hertzman Johansson C; Egyhazi Brage S
Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
[TBL] [Abstract][Full Text] [Related]
19. Achievements and challenges of molecular targeted therapy in melanoma.
Sullivan R; LoRusso P; Boerner S; Dummer R
Am Soc Clin Oncol Educ Book; 2015; ():177-86. PubMed ID: 25993155
[TBL] [Abstract][Full Text] [Related]
20. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]